Amgen
American multinational biopharmaceutical company
AMGN Nasdaq · home listing
4332 Hong Kong Stock Exchange
ISIN US0311621009 SEC CIK 318154 LEI 62QBXGPJ34PQ72Z12S66
Follow Amgen
Weekly email: filings, results
Revenue, last quarter
$10.4B
+8.5% vs same quarter last year
Net income
$3.9B
+20.1% vs same quarter last year
EPS, diluted
$7.08
+19.4% vs same quarter last year
Operating cash flow
$4.2B
−9.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $36.8B | $7.7B |
| FY24 | $33.4B | $4.1B |
| FY23 | $28.2B | $6.7B |
| FY22 | $26.3B | $6.6B |
| FY21 | $26B | $5.9B |
| FY20 | $25.4B | $7.3B |
| FY19 | $23.4B | $7.8B |
| FY18 | $23.7B | $8.4B |
| FY17 | $22.8B | $2B |
| FY16 | $23B | $7.7B |
| FY15 | $21.7B | $6.9B |
| FY14 | $20.1B | $5.2B |
| FY13 | $18.7B | $5.1B |
| FY12 | $17.3B | $4.3B |
| FY11 | $15.6B | $3.7B |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 67.2% | 24.7% | 21% |
| FY24 | 61.5% | 21.7% | 12.2% |
| FY23 | 70% | 28% | 23.8% |
| FY22 | 75.7% | 36.3% | 24.9% |
| FY21 | 75.2% | 29.4% | 22.7% |
| FY20 | 75.8% | 35.9% | 28.6% |
| FY19 | 81.4% | 41.4% | 33.6% |
| FY18 | 82.7% | 43.2% | 35.3% |
| FY17 | 82.2% | 43.6% | 8.7% |
| FY16 | 81.9% | 42.6% | 33.6% |
| FY15 | 80.5% | 39.1% | 32% |
| FY14 | 78% | 30.9% | 25.7% |
| FY13 | 82.1% | 31.4% | 27.2% |
| FY12 | 81.5% | 32.3% | 25.2% |
| FY11 | 82.6% | 27.7% | 23.6% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $8.1B |
| FY24 | $10.4B |
| FY23 | $7.4B |
| FY22 | $8.8B |
| FY21 | $8.4B |
| FY20 | $9.9B |
| FY19 | $8.5B |
| FY18 | $10.6B |
| FY17 | $10.5B |
| FY16 | $9.6B |
| FY15 | $9.1B |
| FY14 | $8.2B |
| FY13 | $5.8B |
| FY12 | $5.2B |
| FY11 | $4.6B |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | $5.1B | $0 |
| FY24 | $4.8B | $200M |
| FY23 | $4.6B | $0 |
| FY22 | $4.2B | $6.4B |
| FY21 | $4B | $5B |
| FY20 | $3.8B | $3.5B |
| FY19 | $3.5B | $7.7B |
| FY18 | $3.5B | $17.8B |
| FY17 | $3.4B | $3.2B |
| FY16 | $3B | $3B |
| FY15 | $2.4B | $1.9B |
| FY14 | $1.9B | $138M |
| FY13 | $1.4B | $832M |
| FY12 | $1.1B | $4.6B |
| FY11 | $500M | $8.3B |
- Amgen
- Healthcare median
Show the numbers
| Year | Amgen | Healthcare median |
|---|---|---|
| FY25 | 21% | −30.6% |
| FY24 | 12.2% | −47% |
| FY23 | 23.8% | −58% |
| FY22 | 24.9% | −80.4% |
| FY21 | 22.7% | −71.9% |
| FY20 | 28.6% | −62.2% |
| FY19 | 33.6% | −46.3% |
| FY18 | 35.3% | −49.6% |
| FY17 | 8.7% | −45.9% |
| FY16 | 33.6% | −36% |
| FY15 | 32% | −38.4% |
| FY14 | 25.7% | −35.5% |
| FY13 | 27.2% | −37.1% |
| FY12 | 25.2% | −29.1% |
| FY11 | 23.6% | −27.9% |